When medtech earnings calls kicked off two weeks ago, a large question loomed over the industry: How badly will the White House’s new tariff policies affect businesses?
The answer from multiple companies has been that it would cost them hundreds of millions of dollars: Johnson & Johnson projected a $400 million hit in 2025, mostly in its medical device segment; Boston Scientific said tariffs would cost the company $200 million; and Abbott, one of the few to not provide a specific figure, said the levies would cost it a “few hundred million dollars.”
15 companies to watch this earnings season
The industry may not be feeling the effects just yet. Boston Scientific executives, for example, said most of the impact would come in the year's second half. Despite these offsets to profits, several top medical device firms have not pulled or lowered guidance for the year — some have even increased it.
MedTech Dive is tracking the tariff impact closely as GE Healthcare, BD, Stryker and Dexcom unveil their latest earnings results this week. Read on for our earnings coverage so far this season:
